At Roche, we focus on developing breakthrough therapies for the world’s hardest-to-treat and rare diseases. These include truly differentiated medicines in cancer, immunology, infectious diseases, ophthalmology and neuroscience.
Roche is a proven healthcare innovator with 26 breakthrough therapy designations as of May 20191 - defined as having made a significant difference or a major advance on the previous standard.
Our pipeline is a source of immense pride and hope. We lead the industry with 72 compounds2 in clinical development underway. This pipeline is delivered through a dedication to the clinical development, registration, sales, marketing and distribution of innovative pharmaceutical medicines that improve patients’ lives.
Locally, Australian patients currently have access to 42 Roche medicines, and we are the leading provider of cancer medicines in Australia by sales. We also invest around $44 million AUD annually in local pharmaceutical research. There are 5,200 patients enrolled in 120+ active clinical trials across the country.2
As validated through US FDA.
From all study sources.
Roche Products Pty Limited ABN 70 000 132 865 | Roche Diagnostics Australia Pty Limited ABN 29 003 001 205 | Roche Diabetes Care Australia Pty Limited ABN 69 602 140 278. This website may contain information about products that are not registered for use in your country of residence and may not comply with applicable laws or regulations in that country. We do not take any responsibility for accessing such information in those circumstances. To report a suspected side effect or product complaint associated with the use of a Roche product, visit